Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Cardiogen Dosage: Community Protocols Explained (2026)

Cardiogen has no clinical-trial-established human dose. The published research is preclinical and mechanistic — review papers and cell-transport modeling, almost entirely from one Russian research group — so every protocol circulating online is community conve

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Cardiogen has no clinical-trial-established human dose. The published research is preclinical and mechanistic — review papers and cell-transport modeling, almost entirely from one Russian research group — so every protocol circulating online is community convention extrapolated from the older Khavinson bioregulators, not a validated regimen. This guide reports those community figures honestly and shows the reconstitution math behind them.

Research-context information only. Cardiogen (the AEDR tetrapeptide) is an unapproved research compound. It has not been evaluated by the FDA for any use, and human clinical data is limited to absent. Doses and protocols below come from vendor listings and self-reported community sources, not controlled trials. This article reports what is documented, not what should be done. Possession or use of research compounds may be restricted in your jurisdiction. Consult a licensed physician for personal medical decisions.

Cardiogen is a short synthetic peptide bioregulator — the tetrapeptide Ala-Glu-Asp-Arg (AEDR) — from the Khavinson family of "peptide bioregulators." It has been described in review work for a proposed role in regulating cardiovascular-cell gene expression tied to inflammaging. Below: the community-reported dosing landscape, the reconstitution math, and an honest read on how thin the evidence is.

Cardiogen Dosing Table

Match your vial size below — reconstitution and dose math update automatically.

1 mg

10 units

0.1 mL

Daily SubQCommunity-reported — no trial-established dose

Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.

Running Cardiogen? Share your protocol

Anonymous · about 20 seconds · see how yours compares

Quick Reference: Community-Reported Protocol

Vial

20 mg (the common Khavinson-peptide format)

BAC Water

2 mL

Concentration

10 mg/mL

Dose

Community-reported, ~0.2-2 mg/day (no trial dose exists)

Route

Subcutaneous (community convention)

Timing

AM (community-reported)

Frequency

Once daily (community-reported)

Course

Short 10-20 day courses, community convention

Storage

Refrigerate, use within 28 days

No trial dose exists. Unlike peptides with published Phase 2 protocols, Cardiogen has only preclinical and mechanistic data behind it. The figures above describe what community sources do, not what evidence supports. For the full profile and vendor pricing, see our Cardiogen peptide page.

Cycling Details

Community sources describe Cardiogen the way the older Khavinson bioregulators were used clinically in Russia — as short, repeated low-dose courses (often 10-20 days) rather than continuous daily dosing. The original rationale, drawn from the bioregulator literature, is that short peptides act as transient signals to gene-expression machinery rather than agents needing steady blood levels (Khavinson & Anisimov, 2009). There is no controlled human data establishing an optimal cycle length for Cardiogen, so this is convention, not evidence.

Routes of Administration

Subcutaneous injection is the route community protocols describe. Some bioregulator products are also sold in sublingual/oral-mucosal formats. No published human trial defines a route for Cardiogen specifically.

Sites: Community protocols describe subcutaneous injection into the abdomen, thigh, or other areas with adequate subcutaneous fat, rotating sites across courses

Volume: Small — at 10 mg/mL even a 1 mg dose is only 0.1 mL

Note: Because the community dose range is low and uncertain, many users dilute generously so small doses are measurable

Reconstitution Quick Reference

20 mg

4 mL

5 mg/mL

20 units

Math: 20 mg / 2 mL = 10 mg/mL. For 1 mg: 1 / 10 = 0.1 mL = 10 units on a 100-unit insulin syringe. For a 0.2 mg (200 mcg) dose at 10 mg/mL, that is just 2 units — which is why many community sources dilute further for measurable volumes.

Community protocols describe swirling gently (not shaking), refrigerating at 2–8°C, and using within 28 days. For the full step-by-step walkthrough, see the Cardiogen Reconstitution Guide.

These figures describe how community sources report reconstituting Cardiogen — not a recommended preparation instruction.

Ready to buy? Compare verified vendors on our best Cardiogen sources page, or browse all coupon codes for up to 50% off.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Cardiogen Dosage, Reconstitution & Mixing Trends

Explore Cardiogen dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. Cardiogen is a short cardiac-targeted peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology, studied for its proposed effects on cardiac tissue regeneration and age-related cardiac function. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting Cardiogen. 92 Cardiogen reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (34 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 20mg (83 sessions). The most common dosing frequency is daily (7x/week) (11 logged protocols), followed by once weekly (1). World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community. All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.

Source: worldpeptideassociation.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →